ШЕРЕР Уоррен Дж. (US),КЛЭПП Артур (US),АНДРЕ Филипп (FR)
申请号：
RU2014119879/15
公开号：
RU2014119879A
申请日:
2012.10.12
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of reducing the flushing of blood to the skin of a face caused by a systematic use of type 5 phosphodiesterase inhibitors by a person, comprising topical application to the skin of the face exposed to flushing of the skin of a person, a composition comprising at least one alpha adrenergic receptor agonist and a locally acceptable carrier in an amount effective to reduce a rush of blood to the skin of the face. 2. The method of claim 1, wherein the composition comprises at least one alpha-1 adrenergic receptor agonist. The method of claim 1, wherein the composition comprises at least one alpha-2 adrenergic receptor agonist. The method of claim 1, wherein the alpha adrenergic receptor agonist is selected from the group consisting of oxymetazoline, tetrahydrozoline, nefazolin, xylometazoline, phenyletherin, methoxamine, mefentermin, metaraminol, desglimidodrin, midodrin, brimonidine, and any pharmaceutically acceptable salt thereof or any combination thereof .5. The method of claim 1, wherein the alpha adrenergic receptor agonist is selected from the group consisting of oxymetazoline, tetrahydrozoline, nefazolin, xylometazoline, phenyletherin, methoxamine, mefentermin, metaraminol, desglimidodrin, midodrin, and pharmaceutically acceptable salts thereof or any combination thereof. 6 . A method according to claim 1, wherein at least one alpha adrenergic receptor agonist or pharmaceutically acceptable salts thereof are selected from the group consisting of brimonidine, oxymetazoline or their pharmaceutically acceptable salts, or any combination of such compounds or salts. The method of claim 1, wherein the sole pharmaceutically active compound1. Способ снижения прилива крови к коже лица, вызванного систематическим применением человеком ингибиторов фосфодиэстеразы типа 5, включающий местное применение в отношении кожи лица, подверженной приливу крови к коже лица человека, композиции, включающей по крайней мере один агонист альфа адренергического рецептора и мес
